---
title: "China’s NMPA approves Akeso’s gumokimab for plaque psoriasis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289582499.md"
description: "China's NMPA has approved Akeso's gumokimab for plaque psoriasis, based on Phase III trial data showing high efficacy and a favorable safety profile. The subcutaneous regimen requires only 17 injections annually, significantly lower than competitors. Akeso CEO Dr. Xia Yu highlighted the drug as part of a differentiated portfolio alongside ebdarokimab. Additionally, the CDE has accepted a supplemental application for gumokimab in active ankylosing spondylitis."
datetime: "2026-06-12T10:16:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289582499.md)
  - [en](https://longbridge.com/en/news/289582499.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289582499.md)
---

# China’s NMPA approves Akeso’s gumokimab for plaque psoriasis

The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies.

Study results showed that gumokimab delivered rapid and strong efficacy.

At week 12 of the Phase III trial, gumokimab achieved a Psoriasis Area and Severity Index 75 (PASI 75) response rate of 94.6% and a complete skin clearance rate (PASI 100) of 47.7%, compared with 28.6% for other agents in the same class.

Durable results were seen through week 52, with a PASI 75 response rate approaching 100% and a PASI 100 response rate of 68.9%.

The safety data also showed a favourable profile for gumokimab, with incidences of treatment-emergent adverse events, serious adverse events, and infections listed among the lowest seen in similar trials of IL-17 inhibitors.

The therapy’s subcutaneous regimen requires only 17 injections annually, including the loading phase, approximately half the injection burden mandated by other IL-17 inhibitors.

Huashan Hospital, Fudan University professor Xu Jinhua is the principal investigator of the study.

Akeso founder, chairwoman, president and CEO Dr Xia Yu said: “To better address patients’ diverse needs, Akeso has successfully developed and launched ebdarokimab and gumokimab, two therapies targeting distinct pathogenic pathways that complement each other.

“The autoimmune disease field remains one of the largest and fastest-growing areas in innovative drug development. With these two approvals, we have built a strong, differentiated portfolio for psoriasis.”

The NMPA’s Center for Drug Evaluation (CDE) has accepted a supplemental new drug application for gumokimab in active ankylosing spondylitis.

The post China’s NMPA approves Akeso’s gumokimab for plaque psoriasis appeared first on Pharmaceutical Business review.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [21:57 ETAkeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio](https://longbridge.com/en/news/289535144.md)
- [UBS Reaffirms Their Buy Rating on Akeso, Inc. (9926)](https://longbridge.com/en/news/289649001.md)
- [Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes](https://longbridge.com/en/news/289413457.md)
- [Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?](https://longbridge.com/en/news/289186879.md)
- [Akeso lung cancer drug trial raises hopes in US$20b market](https://longbridge.com/en/news/288280716.md)